SAN DIEGO, Jan. 30, 2013 /PRNewswire/ -- Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, today announced that Gartner, Inc., the leading provider of research and analysis on the global information technology industry, has rated the company's electronic laboratory notebooks (ELN) as "very high" or "high" in each scientific and functional domain in a recent report on considerations for selecting an ELN. Accelrys was the only vendor with ELNs that achieved those ratings in all categories.
The report, published Jan. 11, 2013 and titled "Manufacturers Must Consider Scientific Domain Expertise During ELN Selection," is based on insights collected by Gartner throughout hundreds of interviews, briefings and interactions with various clients. The Accelrys ELN secured a "very high" rating in chemistry, meaning the product is close to becoming a de facto standard in that category, as well as "high" ratings in biology, formulation, engineering, regulated environments and translational medicine. The Accelrys Laboratory Execution System was rated "very high" in regulated environments and "high" in formulation, while the Contur ELN rated "high" in chemistry.
"In the push to reduce innovation cycle times and share information among scientists and engineers, ELN technologies have the potential to be valuable tools, especially for transferring knowledge from ideas into product development," Gartner research director Michael Shanler said in the report. "However, as companies move toward "end-to-end" informatics solutions that extend from research into manufacturing, deep scientific functionality is often compromised when moving toward single solution providers. While IT often weights value for lower cost, simple governance and architecture simplicity, R&D sees deep scientific functionality as the primary criterion for sustaining innovation.""With deep scientific domain experience and an integrated set of solutions for optimizing the lab-to-commercialization value chain – from research through downstream analytical development, quality control, quality assurance and manufacturing – Accelrys is proving that neither functionality nor expertise should be compromised in the quest to improve innovation," said Accelrys President and CEO Max Carnecchia. "We believe Gartner's 'high' and 'very high' ratings of our ELNs confirm our industry leading position in the market and our ability to deliver a breadth of solutions across scientific and functional domains for a diverse and global customer base." About Accelrys, Inc.Accelrys, Inc. (NASDAQ: ACCL), a leading provider of scientific innovation lifecycle management software, supports industries and organizations that rely on scientific innovation to differentiate themselves. The industry-leading Accelrys Enterprise Platform provides a broad and flexible scientific solution optimized to integrate the diversity of science, experimental processes and information requirements across the research, development, process scale-up and early manufacturing phases of product development. By incorporating capabilities in applications for modeling and simulation, enterprise lab management, workflow and automation, and data management and informatics, Accelrys enables scientific innovators to access, organize, analyze and share data in unprecedented ways, ultimately enhancing innovation, improving productivity and compliance, reducing costs and speeding time from lab to market. Accelrys solutions are used by more than 1,300 companies in the pharmaceutical, biotechnology, energy, chemicals, aerospace, consumer packaged goods and industrial products industries. Headquartered in San Diego, California, USA, Accelrys employs more than 200 full-time PhD scientists. For more information about Accelrys, visit www.accelrys.com. SOURCE Accelrys, Inc.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV